These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29322928)

  • 1. Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model.
    Asami S; Kiga D; Konagaya A
    BMC Syst Biol; 2017 Dec; 11(Suppl 7):129. PubMed ID: 29322928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models.
    Yoshida K; Maeda K; Kusuhara H; Konagaya A
    BMC Syst Biol; 2013 Oct; 7 Suppl 3(Suppl 3):S3. PubMed ID: 24555857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.
    Bouchene S; Marchand S; Couet W; Friberg LE; Gobin P; Lamarche I; Grégoire N; Björkman S; Karlsson MO
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):407-422. PubMed ID: 29665289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.
    Björkman S
    J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):285-307. PubMed ID: 14650375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs.
    Munir A; Azam S; Fazal S; Bhatti AI
    J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models.
    Toshimoto K
    Drug Metab Pharmacokinet; 2024 Jun; 56():101011. PubMed ID: 38833901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method.
    Yoshida K; Maeda K; Konagaya A; Kusuhara H
    Drug Metab Dispos; 2018 Nov; 46(11):1805-1816. PubMed ID: 30135241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
    Sadiq MW; Nielsen EI; Khachman D; Conil JM; Georges B; Houin G; Laffont CM; Karlsson MO; Friberg LE
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):69-79. PubMed ID: 27578330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution.
    Yau E; Olivares-Morales A; Gertz M; Parrott N; Darwich AS; Aarons L; Ogungbenro K
    AAPS J; 2020 Feb; 22(2):41. PubMed ID: 32016678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consideration of Fractional Distribution Parameter f
    Jeong YS; Jusko WJ
    Pharm Res; 2022 Mar; 39(3):463-479. PubMed ID: 35288804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly.
    Thompson CM; Johns DO; Sonawane B; Barton HA; Hattis D; Tardif R; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2009 Jan; 12(1):1-24. PubMed ID: 19117207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.
    Edginton AN; Theil FP; Schmitt W; Willmann S
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1143-52. PubMed ID: 18721109
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Li X; Jusko WJ
    Drug Metab Dispos; 2022 Oct; ():. PubMed ID: 36195337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
    Edginton AN; Willmann S
    Clin Pharmacokinet; 2008; 47(11):743-52. PubMed ID: 18840029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models II: Practical Application of Tissue Lumping Theories for Pharmacokinetics of Various Compounds.
    Jeong YS; Kim MS; Chung SJ
    AAPS J; 2022 Aug; 24(5):91. PubMed ID: 36002779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound.
    Yun YE; Cotton CA; Edginton AN
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):1-14. PubMed ID: 24258064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.